DB:OXOA

Stock Analysis Report

Executive Summary

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson’s disease, central nervous system disorders, and ophthalmology in Europe and internationally.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Oxford BioMedica's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OXOA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

38.0%

OXOA

3.0%

DE Biotechs

9.1%

DE Market


1 Year Return

4.4%

OXOA

-9.5%

DE Biotechs

-13.1%

DE Market

Return vs Industry: OXOA exceeded the German Biotechs industry which returned -9% over the past year.

Return vs Market: OXOA exceeded the German Market which returned -14.3% over the past year.


Shareholder returns

OXOAIndustryMarket
7 Day38.0%3.0%9.1%
30 Day36.3%1.5%-1.0%
90 Day6.9%-23.9%-20.7%
1 Year4.4%4.4%-9.2%-9.5%-10.6%-13.1%
3 Year245.1%245.1%17.1%15.9%-10.7%-18.1%
5 Year-6.7%-6.7%-8.7%-11.1%-10.7%-22.8%

Price Volatility Vs. Market

How volatile is Oxford BioMedica's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Oxford BioMedica undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OXOA (€8.63) is trading below our estimate of fair value (€22.21)

Significantly Below Fair Value: OXOA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OXOA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OXOA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OXOA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OXOA is overvalued based on its PB Ratio (6.4x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Oxford BioMedica forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-0.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OXOA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OXOA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OXOA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OXOA's revenue (17.8% per year) is forecast to grow faster than the German market (3.9% per year).

High Growth Revenue: OXOA's revenue (17.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OXOA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Oxford BioMedica performed over the past 5 years?

24.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OXOA is currently unprofitable.

Growing Profit Margin: OXOA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OXOA is unprofitable, but has reduced losses over the past 5 years at a rate of 24.7% per year.

Accelerating Growth: Unable to compare OXOA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OXOA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.9%).


Return on Equity

High ROE: OXOA has a negative Return on Equity (-9.73%), as it is currently unprofitable.


Next Steps

Financial Health

How is Oxford BioMedica's financial position?


Financial Position Analysis

Short Term Liabilities: OXOA's short term assets (£75.1M) exceed its short term liabilities (£34.0M).

Long Term Liabilities: OXOA's short term assets (£75.1M) exceed its long term liabilities (£14.9M).


Debt to Equity History and Analysis

Debt Level: OXOA is debt free.

Reducing Debt: OXOA has no debt compared to 5 years ago when its debt to equity ratio was 4.1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if OXOA has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OXOA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Oxford BioMedica's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OXOA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OXOA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OXOA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OXOA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OXOA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

John Dawson (59yo)

11.5s

Tenure

UK£1,311,000

Compensation

Mr. John Dawson has been the Chief Executive Officer of Oxford BioMedica PLC since October 13, 2008. Mr. Dawson has broad experience in European commercial activities, finance and in mergers and acquisitio ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD1.63M) is about average for companies of similar size in the German market ($USD1.31M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Dawson
CEO & Executive Director11.5yrsUK£1.31m0.12% £710.5k
Stuart Paynter
CFO, Company Secretary & Director2.67yrsUK£501.00k0.0088% £54.4k
Peter Nolan
Consultant1.75yrsUK£520.00kno data
Nick Page
Chief Operations Officer2yrsno datano data
James Miskin
Chief Technical Officerno datano datano data
Kyriacos Mitrophanous
Chief Scientific Officerno datano data0.20% £1.2m
Catherine Isted
Head of Corporate Development & IRno datano datano data
Natalie Walter
General Counsel0.92yrno data0.0023% £14.1k
Sarah Macleod
Head of Communicationsno datano datano data
Helen Stephenson-Ellis
Chief People Officer2yrsno datano data

2.0yrs

Average Tenure

59yo

Average Age

Experienced Management: OXOA's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Dawson
CEO & Executive Director11.5yrsUK£1.31m0.12% £710.5k
Stuart Paynter
CFO, Company Secretary & Director2.67yrsUK£501.00k0.0088% £54.4k
William Langston
Member of Scientific Advisory Boardno datano datano data
Andrew John Heath
Deputy Chairman & Senior Independent Director8.92yrsUK£65.00k0.072% £441.7k
Peter Stern
Member of Scientific Advisory Boardno datano datano data
Krystof Bankiewicz
Member of Scientific Advisory Boardno datano datano data
Lorenzo Tallarigo
Non-Executive Chairman4.17yrsUK£150.00k0.071% £435.8k
Heather Preston
Independent Non-Executive Director2.08yrsUK£52.00kno data
Martin Diggle
Non-Executive Director7.5yrsno datano data
Stuart Henderson
Independent Non-Executive Director3.83yrsUK£65.00k0.010% £63.6k

4.2yrs

Average Tenure

59yo

Average Age

Experienced Board: OXOA's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OXOA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.4%.


Top Shareholders

Company Information

Oxford BioMedica plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oxford BioMedica plc
  • Ticker: OXOA
  • Exchange: DB
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£542.200m
  • Listing Market Cap: UK£617.664m
  • Shares outstanding: 76.91m
  • Website: https://www.oxfordbiomedica.co.uk

Number of Employees


Location

  • Oxford BioMedica plc
  • Windrush Court
  • Transport Way
  • Oxford
  • Oxfordshire
  • OX4 6LT
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OXOADB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 1996
OXBLSE (London Stock Exchange)YesOrdinary SharesGBGBPDec 1996
OXBD.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 1996
OXBLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPDec 1996

Biography

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson’s disease, central nervous system disorders, and ophthalmology in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company’s proprietary products under development stage include OXB-202, which is in a Phase I/II trial preparation for the prevention of corneal graft rejection; OXB-302 that has completed pre-clinical development for use in the treatment of a range of cancers; and OXB-201, which completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. The company’s products in preclinical stage include OXB-204 and OXB-208 for the treatment of ophthalmology; and OXB-103 for the treatment of CNS disorders. Oxford BioMedica plc has partnerships with Novartis, Sanofi, Orchard Therapeutics, Bioverativ, Axovant Gene Therapies, Santen, the UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim, Imperial Innovations, and Microsoft. The company was founded in 1995 and is headquartered in Oxford, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/09 22:27
End of Day Share Price2020/04/09 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.